Oncology - European Medical Journal

This site is intended for healthcare professionals

Continue

Oncology

Filter
22 May 2018

6-Month Course of Herceptin Just as Effective as 12 Months in Breast Cancer Treatment

Herceptin treatment for women with HER2-positive early-stage breast cancer is just as effective when taken for 6 months in preventing relapse and death…
15 May 2018

Oral Drug Can Prevent Recurrence of Venous Thromboembolism in Cancer Patients

Cancer patients can be protected from further recurrence of venous thromboembolism (VTE) with an oral drug, suggests results of a study from the…
25 Apr 2018

Machine Modelling Technique Enables Greater Confidence in Assessing Cancer Treatments

Efficacy of cancer treatments could be more effectively measured using an adaptation of a machine learning approach originally designed to help…
20 Apr 2018

New Discovery Could Help Overcome Chemoresistance in a Form of Breast Cancer

Improved care for triple-negative breast cancer (TNBC) could take place following the discovery that the condition is chemoresistant even before…
19 Apr 2018

Engineered T Cells Shown to Eliminate Paediatric Brain Cancer

Elimination of a paediatric brain tumour called diffuse intrinsic pontine glioma (DIPG) has successfully taken place in a mouse model through the…
17 Apr 2018

Trial Results Lead to Calls for all Advanced NSCLC Patients to Receive Immunotherapy

All patients with advanced non-small-cell lung cancer (NSCLC) should receive immunotherapy according to Prof Solange Peters, ESMO President Elect…
12 Apr 2018

Cancer Genetic Mutations Not All Treatable: System to Rank Relevance of Mutations Needed

ESMO, the leading professional organisation for medical oncology, welcomes the latest reports from The Cancer Genome Atlas (TCGA) as a major…
6 Apr 2018

Discovery of Mutations that are Functional in Cancer Could Provide New Treatment Targets

Potential new targets for cancer treatments have been identified following the discovery of nearly 200 mutations in non-coding DNA that have a functional…
We’ve noticed you’re accessing
from North/South America.